Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, ...
Comparative transcriptomic analysis to identify similarities and therapeutic vulnerabilities in olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated ...
A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer known as oropharyngeal cancer. A rare ...
Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Neoadjuvant approaches for HER2-positive breast cancer continue ...
In this systematic review and cohort study, researchers aimed to determine whether receipt of guideline-concordant systemic therapy is associated with OS in iCCA patients.
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence In the interim analysis of the ...
Depending on the disease specifics, patients with melanoma may undergo pre- or post-surgical therapies. Skin melanoma, one of the most serious forms of skin cancer, poses a significant threat to ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.
Nisha Mohindra, MD, and Christopher Towe, MD, discuss what early-stage non-small cell lung cancer treatment options have looked like in the past and a more recent treatment option, neoadjuvant therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results